Alan Palestine
Concepts (701)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uveitis | 72 | 2025 | 150 | 7.350 |
Why?
| | Panuveitis | 4 | 2023 | 7 | 2.960 |
Why?
| | Eye Infections, Bacterial | 7 | 2026 | 45 | 2.780 |
Why?
| | Visual Acuity | 37 | 2026 | 490 | 2.770 |
Why?
| | Endophthalmitis | 7 | 2026 | 46 | 2.550 |
Why?
| | Fluocinolone Acetonide | 4 | 2024 | 15 | 2.280 |
Why?
| | Uveitis, Intermediate | 4 | 2023 | 8 | 2.170 |
Why?
| | Fluorescein Angiography | 23 | 2026 | 189 | 2.150 |
Why?
| | Cataract | 6 | 2023 | 238 | 2.060 |
Why?
| | Glucocorticoids | 11 | 2026 | 532 | 2.040 |
Why?
| | Tomography, Optical Coherence | 15 | 2026 | 270 | 1.980 |
Why?
| | Scleritis | 5 | 2025 | 28 | 1.790 |
Why?
| | Macular Degeneration | 12 | 2025 | 191 | 1.760 |
Why?
| | Macular Edema | 6 | 2026 | 49 | 1.650 |
Why?
| | Geographic Atrophy | 10 | 2025 | 97 | 1.590 |
Why?
| | Retinopathy of Prematurity | 8 | 2020 | 181 | 1.580 |
Why?
| | Vitrectomy | 8 | 2020 | 73 | 1.440 |
Why?
| | Corneal Ulcer | 2 | 2022 | 20 | 1.440 |
Why?
| | Ocular Hypertension | 6 | 2026 | 70 | 1.440 |
Why?
| | Intraocular Pressure | 14 | 2026 | 330 | 1.340 |
Why?
| | Vitreous Body | 15 | 2022 | 117 | 1.170 |
Why?
| | Cytomegalovirus Retinitis | 6 | 2024 | 22 | 1.170 |
Why?
| | Arthritis, Juvenile | 2 | 2022 | 60 | 1.160 |
Why?
| | Glaucoma | 4 | 2025 | 251 | 1.040 |
Why?
| | Corneal Transplantation | 6 | 2025 | 17 | 0.960 |
Why?
| | Cyclosporins | 31 | 1991 | 71 | 0.930 |
Why?
| | Uveitis, Anterior | 7 | 2026 | 27 | 0.930 |
Why?
| | Retinal Vasculitis | 2 | 2026 | 12 | 0.910 |
Why?
| | Wet Macular Degeneration | 6 | 2025 | 58 | 0.900 |
Why?
| | Retinal Diseases | 7 | 2025 | 101 | 0.880 |
Why?
| | Cataract Extraction | 4 | 2023 | 120 | 0.860 |
Why?
| | Postoperative Complications | 7 | 2021 | 2977 | 0.840 |
Why?
| | Drug Costs | 2 | 2016 | 117 | 0.820 |
Why?
| | Humans | 191 | 2026 | 145763 | 0.820 |
Why?
| | Retrospective Studies | 40 | 2026 | 17325 | 0.810 |
Why?
| | Retinal Vessels | 6 | 2021 | 77 | 0.800 |
Why?
| | Registries | 9 | 2025 | 2410 | 0.780 |
Why?
| | Diabetic Retinopathy | 3 | 2026 | 209 | 0.780 |
Why?
| | Uveitis, Posterior | 5 | 2019 | 12 | 0.770 |
Why?
| | Methotrexate | 4 | 2025 | 233 | 0.770 |
Why?
| | Anterior Chamber | 5 | 2021 | 26 | 0.760 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2026 | 251 | 0.760 |
Why?
| | Keratoconjunctivitis Sicca | 1 | 2022 | 4 | 0.750 |
Why?
| | Retinal Detachment | 3 | 2020 | 73 | 0.740 |
Why?
| | Antirheumatic Agents | 2 | 2022 | 307 | 0.740 |
Why?
| | Inflammation | 10 | 2023 | 2883 | 0.730 |
Why?
| | Retinitis | 15 | 1993 | 21 | 0.730 |
Why?
| | Eye Diseases | 10 | 2020 | 97 | 0.730 |
Why?
| | Azathioprine | 3 | 2025 | 44 | 0.720 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2020 | 699 | 0.720 |
Why?
| | Behcet Syndrome | 7 | 2021 | 19 | 0.710 |
Why?
| | Staphylococcus aureus | 1 | 2026 | 453 | 0.710 |
Why?
| | Health Care Costs | 2 | 2016 | 425 | 0.700 |
Why?
| | Staphylococcal Infections | 1 | 2026 | 393 | 0.690 |
Why?
| | Retinal Drusen | 4 | 2024 | 31 | 0.690 |
Why?
| | Drug Implants | 6 | 2024 | 83 | 0.690 |
Why?
| | Acquired Immunodeficiency Syndrome | 22 | 1996 | 237 | 0.680 |
Why?
| | Eye Banks | 1 | 2020 | 7 | 0.650 |
Why?
| | Follow-Up Studies | 21 | 2026 | 5428 | 0.610 |
Why?
| | Complement Activation | 5 | 2025 | 399 | 0.610 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2020 | 47 | 0.610 |
Why?
| | Aged | 54 | 2026 | 26215 | 0.610 |
Why?
| | Autoimmune Diseases | 21 | 2025 | 469 | 0.610 |
Why?
| | Choroid | 13 | 2025 | 80 | 0.600 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2019 | 70 | 0.590 |
Why?
| | Male | 102 | 2026 | 73003 | 0.570 |
Why?
| | Homosexuality, Male | 1 | 2020 | 231 | 0.570 |
Why?
| | Aged, 80 and over | 22 | 2026 | 8346 | 0.560 |
Why?
| | Female | 117 | 2026 | 79035 | 0.560 |
Why?
| | Ophthalmology | 4 | 2025 | 120 | 0.550 |
Why?
| | Middle Aged | 66 | 2026 | 36302 | 0.550 |
Why?
| | Adult | 80 | 2026 | 40872 | 0.540 |
Why?
| | Practice Patterns, Physicians' | 3 | 2016 | 1372 | 0.530 |
Why?
| | Surveys and Questionnaires | 9 | 2025 | 6085 | 0.530 |
Why?
| | Conjunctivitis | 3 | 2024 | 30 | 0.520 |
Why?
| | Cytomegalovirus | 3 | 2022 | 168 | 0.520 |
Why?
| | International Classification of Diseases | 1 | 2018 | 150 | 0.520 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2019 | 224 | 0.520 |
Why?
| | Adrenal Cortex Hormones | 4 | 2023 | 484 | 0.510 |
Why?
| | Sarcoidosis | 9 | 2023 | 163 | 0.500 |
Why?
| | Labor, Induced | 1 | 2017 | 40 | 0.500 |
Why?
| | Labor, Obstetric | 1 | 2017 | 68 | 0.490 |
Why?
| | Rheumatologists | 1 | 2016 | 15 | 0.490 |
Why?
| | Ophthalmologists | 1 | 2016 | 21 | 0.480 |
Why?
| | Polychondritis, Relapsing | 1 | 2015 | 1 | 0.470 |
Why?
| | Ear Auricle | 1 | 2015 | 14 | 0.460 |
Why?
| | Complement System Proteins | 4 | 2025 | 314 | 0.460 |
Why?
| | Insurance, Health | 2 | 2016 | 311 | 0.450 |
Why?
| | Disease Management | 3 | 2025 | 653 | 0.440 |
Why?
| | Vision Disorders | 2 | 2016 | 179 | 0.440 |
Why?
| | Needles | 1 | 2015 | 63 | 0.440 |
Why?
| | Anti-Bacterial Agents | 4 | 2026 | 1925 | 0.440 |
Why?
| | Neonatal Screening | 4 | 2018 | 179 | 0.440 |
Why?
| | Biopsy, Needle | 1 | 2015 | 185 | 0.430 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 1582 | 0.430 |
Why?
| | DNA, Viral | 1 | 2016 | 356 | 0.420 |
Why?
| | Surgical Wound Infection | 1 | 2018 | 329 | 0.420 |
Why?
| | Diabetes Mellitus | 2 | 2022 | 1101 | 0.410 |
Why?
| | Biomarkers | 10 | 2025 | 4302 | 0.410 |
Why?
| | Eye Infections, Viral | 3 | 2026 | 12 | 0.400 |
Why?
| | Intravitreal Injections | 3 | 2026 | 71 | 0.400 |
Why?
| | Immunosuppressive Agents | 6 | 2025 | 838 | 0.400 |
Why?
| | Multimodal Imaging | 2 | 2025 | 129 | 0.400 |
Why?
| | Bacteria | 2 | 2018 | 766 | 0.390 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 1180 | 0.390 |
Why?
| | Fundus Oculi | 10 | 2025 | 89 | 0.380 |
Why?
| | Premature Birth | 1 | 2017 | 390 | 0.380 |
Why?
| | Melanoma | 1 | 2019 | 761 | 0.370 |
Why?
| | Cytomegalovirus Infections | 12 | 1999 | 206 | 0.370 |
Why?
| | Databases, Factual | 1 | 2018 | 1491 | 0.370 |
Why?
| | Vaccination | 1 | 2021 | 1428 | 0.370 |
Why?
| | Colorado | 11 | 2025 | 4556 | 0.360 |
Why?
| | Gestational Age | 8 | 2020 | 989 | 0.360 |
Why?
| | Skin Neoplasms | 2 | 2019 | 852 | 0.360 |
Why?
| | Antiviral Agents | 11 | 2022 | 769 | 0.360 |
Why?
| | Steroids | 2 | 2023 | 160 | 0.350 |
Why?
| | Antineoplastic Agents | 3 | 2020 | 2219 | 0.340 |
Why?
| | Placenta | 1 | 2018 | 787 | 0.340 |
Why?
| | AIDS-Related Opportunistic Infections | 3 | 2022 | 130 | 0.340 |
Why?
| | Graft Rejection | 4 | 2025 | 521 | 0.330 |
Why?
| | Pars Planitis | 2 | 2026 | 6 | 0.330 |
Why?
| | Macula Lutea | 3 | 2020 | 21 | 0.320 |
Why?
| | Adolescent | 33 | 2026 | 22573 | 0.320 |
Why?
| | Ciliary Body | 9 | 2018 | 40 | 0.320 |
Why?
| | Trabeculectomy | 2 | 2022 | 75 | 0.310 |
Why?
| | Electronic Health Records | 1 | 2018 | 1202 | 0.310 |
Why?
| | Complement Factor B | 2 | 2022 | 106 | 0.310 |
Why?
| | Organ Transplantation | 2 | 2024 | 253 | 0.300 |
Why?
| | United States | 13 | 2025 | 16123 | 0.300 |
Why?
| | Ganciclovir | 9 | 2022 | 53 | 0.300 |
Why?
| | Cross-Sectional Studies | 9 | 2025 | 5922 | 0.290 |
Why?
| | Glaucoma, Open-Angle | 2 | 2022 | 104 | 0.290 |
Why?
| | Aqueous Humor | 4 | 2022 | 40 | 0.280 |
Why?
| | Adalimumab | 3 | 2025 | 54 | 0.280 |
Why?
| | Antigens | 14 | 1990 | 348 | 0.280 |
Why?
| | Child | 24 | 2026 | 22739 | 0.260 |
Why?
| | Eye Proteins | 7 | 1990 | 92 | 0.260 |
Why?
| | Conjunctival Diseases | 3 | 2017 | 23 | 0.260 |
Why?
| | Retinal Pigment Epithelium | 3 | 2024 | 79 | 0.260 |
Why?
| | Incidence | 7 | 2024 | 2933 | 0.260 |
Why?
| | Young Adult | 11 | 2026 | 14251 | 0.260 |
Why?
| | Cyclosporine | 2 | 2022 | 256 | 0.250 |
Why?
| | Retina | 18 | 1993 | 329 | 0.250 |
Why?
| | Birth Weight | 4 | 2020 | 517 | 0.250 |
Why?
| | Mycophenolic Acid | 3 | 2025 | 119 | 0.250 |
Why?
| | Keratitis | 3 | 2025 | 20 | 0.250 |
Why?
| | Risk Factors | 12 | 2025 | 10917 | 0.240 |
Why?
| | Corneal Diseases | 5 | 2017 | 46 | 0.240 |
Why?
| | Time Factors | 13 | 2025 | 7133 | 0.230 |
Why?
| | Leprosy, Lepromatous | 1 | 2025 | 8 | 0.230 |
Why?
| | Fovea Centralis | 1 | 2025 | 24 | 0.230 |
Why?
| | Acanthamoeba Keratitis | 1 | 2025 | 4 | 0.230 |
Why?
| | Opportunistic Infections | 4 | 1991 | 47 | 0.230 |
Why?
| | Pemphigoid, Benign Mucous Membrane | 2 | 2024 | 6 | 0.230 |
Why?
| | Eye Infections, Parasitic | 1 | 2025 | 7 | 0.230 |
Why?
| | Biological Factors | 2 | 2022 | 39 | 0.230 |
Why?
| | Chemokine CCL5 | 2 | 2023 | 40 | 0.220 |
Why?
| | Child, Preschool | 11 | 2026 | 11868 | 0.220 |
Why?
| | Bromocriptine | 4 | 1990 | 31 | 0.220 |
Why?
| | Herpesvirus 4, Human | 1 | 2026 | 172 | 0.220 |
Why?
| | Tertiary Care Centers | 1 | 2026 | 195 | 0.220 |
Why?
| | Academies and Institutes | 1 | 2025 | 61 | 0.210 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2026 | 101 | 0.210 |
Why?
| | Withholding Treatment | 1 | 2025 | 80 | 0.210 |
Why?
| | Papilledema | 2 | 2024 | 44 | 0.210 |
Why?
| | Specialization | 2 | 2016 | 137 | 0.210 |
Why?
| | Tuberculosis, Ocular | 1 | 2024 | 8 | 0.210 |
Why?
| | Retinal Vein Occlusion | 1 | 2004 | 14 | 0.210 |
Why?
| | Interferon-gamma Release Tests | 1 | 2024 | 32 | 0.200 |
Why?
| | Laser Therapy | 5 | 2021 | 144 | 0.200 |
Why?
| | Treatment Outcome | 12 | 2026 | 11793 | 0.200 |
Why?
| | Fluoresceins | 5 | 1989 | 48 | 0.200 |
Why?
| | Infant, Premature | 2 | 2019 | 620 | 0.200 |
Why?
| | Infant | 9 | 2022 | 10090 | 0.200 |
Why?
| | Advisory Committees | 1 | 2025 | 229 | 0.190 |
Why?
| | Optic Disk | 1 | 2024 | 53 | 0.190 |
Why?
| | Cohort Studies | 7 | 2020 | 6032 | 0.190 |
Why?
| | Infant, Very Low Birth Weight | 3 | 2018 | 75 | 0.190 |
Why?
| | Phacoemulsification | 3 | 2019 | 123 | 0.190 |
Why?
| | Anti-Inflammatory Agents | 3 | 2022 | 478 | 0.190 |
Why?
| | Etanercept | 1 | 2022 | 60 | 0.190 |
Why?
| | Histocompatibility Antigens Class II | 9 | 1994 | 364 | 0.190 |
Why?
| | Foscarnet | 4 | 1996 | 22 | 0.180 |
Why?
| | Algorithms | 4 | 2018 | 1850 | 0.180 |
Why?
| | Tonometry, Ocular | 4 | 2026 | 104 | 0.180 |
Why?
| | Eye Neoplasms | 3 | 2017 | 30 | 0.180 |
Why?
| | Quality of Life | 3 | 2023 | 3210 | 0.180 |
Why?
| | Reference Standards | 2 | 2022 | 177 | 0.180 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2024 | 552 | 0.170 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 8 | 0.170 |
Why?
| | Albumins | 1 | 2022 | 119 | 0.170 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.170 |
Why?
| | Tacrolimus | 1 | 2022 | 196 | 0.170 |
Why?
| | Capsule Opacification | 1 | 2021 | 22 | 0.170 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 22 | 0.170 |
Why?
| | Rats, Inbred Lew | 18 | 1994 | 105 | 0.170 |
Why?
| | Antihypertensive Agents | 1 | 2025 | 521 | 0.170 |
Why?
| | T-Lymphocytes, Helper-Inducer | 8 | 1994 | 132 | 0.170 |
Why?
| | National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.170 |
Why?
| | Sensitivity and Specificity | 4 | 2018 | 2000 | 0.160 |
Why?
| | Antibodies, Monoclonal | 12 | 2020 | 1505 | 0.160 |
Why?
| | Laser Coagulation | 2 | 2018 | 80 | 0.160 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2020 | 23 | 0.160 |
Why?
| | Administration, Topical | 4 | 2016 | 155 | 0.150 |
Why?
| | Scleral Buckling | 1 | 2019 | 16 | 0.150 |
Why?
| | Endotoxins | 3 | 1991 | 217 | 0.150 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 29 | 0.150 |
Why?
| | Anemia, Sickle Cell | 1 | 2004 | 318 | 0.150 |
Why?
| | Diagnostic Techniques, Ophthalmological | 2 | 2018 | 53 | 0.150 |
Why?
| | Multiple Sclerosis | 3 | 2023 | 489 | 0.150 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2022 | 1217 | 0.150 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 38 | 0.150 |
Why?
| | Canada | 1 | 2020 | 432 | 0.150 |
Why?
| | Complement C3a | 1 | 2019 | 40 | 0.150 |
Why?
| | Acyclovir | 5 | 2001 | 98 | 0.140 |
Why?
| | Transplantation, Autologous | 1 | 2020 | 301 | 0.140 |
Why?
| | Infant, Newborn | 7 | 2020 | 6464 | 0.140 |
Why?
| | Pyrimidinones | 1 | 2019 | 125 | 0.140 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 143 | 0.140 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 56 | 0.140 |
Why?
| | Computer Systems | 1 | 2018 | 55 | 0.140 |
Why?
| | Prospective Studies | 8 | 2025 | 8075 | 0.140 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2018 | 19 | 0.140 |
Why?
| | Organophosphonates | 1 | 1998 | 95 | 0.140 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 273 | 0.130 |
Why?
| | Rats | 25 | 2025 | 5585 | 0.130 |
Why?
| | Viral Load | 2 | 2016 | 526 | 0.130 |
Why?
| | Risk | 4 | 2018 | 923 | 0.130 |
Why?
| | Decision Making | 2 | 2016 | 982 | 0.130 |
Why?
| | Disease-Free Survival | 1 | 2019 | 770 | 0.130 |
Why?
| | Metformin | 1 | 2021 | 329 | 0.130 |
Why?
| | Farber Lipogranulomatosis | 1 | 2017 | 4 | 0.130 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 199 | 0.130 |
Why?
| | Biological Products | 1 | 2021 | 257 | 0.130 |
Why?
| | Amnion | 1 | 2017 | 31 | 0.130 |
Why?
| | Synovitis | 1 | 2017 | 35 | 0.120 |
Why?
| | Parity | 1 | 2017 | 111 | 0.120 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2017 | 37 | 0.120 |
Why?
| | Arrestin | 13 | 1990 | 14 | 0.120 |
Why?
| | Ophthalmoscopy | 1 | 2016 | 38 | 0.120 |
Why?
| | Reoperation | 1 | 2020 | 637 | 0.120 |
Why?
| | Herpes Zoster | 2 | 2009 | 319 | 0.120 |
Why?
| | Medical Informatics | 1 | 2017 | 100 | 0.120 |
Why?
| | Cicatrix | 1 | 2017 | 69 | 0.120 |
Why?
| | Arthritis | 1 | 2017 | 96 | 0.120 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 1043 | 0.120 |
Why?
| | Infant, Low Birth Weight | 1 | 2017 | 156 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2023 | 1751 | 0.120 |
Why?
| | Drug Therapy, Combination | 6 | 2025 | 1043 | 0.120 |
Why?
| | Transplantation, Homologous | 2 | 2016 | 419 | 0.120 |
Why?
| | Lymphocytes | 9 | 1991 | 376 | 0.120 |
Why?
| | T-Lymphocytes | 12 | 2022 | 1997 | 0.110 |
Why?
| | Microbiological Techniques | 1 | 2015 | 30 | 0.110 |
Why?
| | Colony Count, Microbial | 1 | 2015 | 89 | 0.110 |
Why?
| | Terminology as Topic | 1 | 2017 | 259 | 0.110 |
Why?
| | Infliximab | 3 | 2025 | 111 | 0.110 |
Why?
| | Recovery of Function | 1 | 2019 | 716 | 0.110 |
Why?
| | Endoscopy | 1 | 2018 | 317 | 0.110 |
Why?
| | Burnout, Professional | 1 | 2022 | 488 | 0.110 |
Why?
| | Weight Gain | 2 | 2016 | 561 | 0.110 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2017 | 198 | 0.110 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 317 | 0.110 |
Why?
| | Ophthalmic Solutions | 2 | 2026 | 82 | 0.110 |
Why?
| | Phosphonoacetic Acid | 2 | 1991 | 10 | 0.110 |
Why?
| | Rheumatology | 1 | 2016 | 133 | 0.110 |
Why?
| | Pregnancy | 2 | 2018 | 7215 | 0.110 |
Why?
| | Lymphocyte Activation | 8 | 1990 | 1133 | 0.110 |
Why?
| | Hematologic Neoplasms | 1 | 2016 | 168 | 0.100 |
Why?
| | Health Care Surveys | 1 | 2016 | 536 | 0.100 |
Why?
| | Chorioretinitis | 2 | 1992 | 8 | 0.100 |
Why?
| | Toxoplasmosis, Ocular | 2 | 1994 | 3 | 0.100 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2019 | 420 | 0.100 |
Why?
| | Disease Progression | 4 | 2025 | 2865 | 0.100 |
Why?
| | Fetus | 1 | 2018 | 804 | 0.100 |
Why?
| | Reproducibility of Results | 2 | 2018 | 3416 | 0.100 |
Why?
| | Physicians | 1 | 2022 | 956 | 0.100 |
Why?
| | Lymphoma, B-Cell | 2 | 1993 | 141 | 0.090 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 981 | 0.090 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 364 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 1998 | 1146 | 0.090 |
Why?
| | Research Design | 1 | 2019 | 1139 | 0.090 |
Why?
| | Kidney Diseases | 6 | 1989 | 426 | 0.090 |
Why?
| | Health Surveys | 1 | 2014 | 520 | 0.090 |
Why?
| | Iris | 3 | 1991 | 23 | 0.090 |
Why?
| | Creatinine | 7 | 1992 | 515 | 0.090 |
Why?
| | HIV-1 | 1 | 1998 | 908 | 0.090 |
Why?
| | HLA Antigens | 7 | 1991 | 240 | 0.090 |
Why?
| | Patient Selection | 1 | 2016 | 739 | 0.090 |
Why?
| | Risk Assessment | 2 | 2019 | 3752 | 0.090 |
Why?
| | Mothers | 1 | 2018 | 765 | 0.090 |
Why?
| | Retinal Necrosis Syndrome, Acute | 1 | 1991 | 7 | 0.090 |
Why?
| | Injections, Intravenous | 7 | 1999 | 197 | 0.090 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 1992 | 195 | 0.090 |
Why?
| | Capillary Permeability | 2 | 1991 | 132 | 0.080 |
Why?
| | Immunologic Factors | 2 | 2024 | 260 | 0.080 |
Why?
| | HIV | 4 | 2020 | 251 | 0.080 |
Why?
| | Animals | 35 | 2025 | 38097 | 0.080 |
Why?
| | Bacterial Infections | 3 | 1989 | 246 | 0.080 |
Why?
| | Antigens, Surface | 3 | 1989 | 155 | 0.080 |
Why?
| | Cytophagaceae | 1 | 1990 | 1 | 0.080 |
Why?
| | Toxoplasma | 2 | 1994 | 49 | 0.080 |
Why?
| | Capnocytophaga | 1 | 1990 | 2 | 0.080 |
Why?
| | Patient Care Team | 1 | 2016 | 697 | 0.080 |
Why?
| | Granuloma | 4 | 2023 | 97 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1969 | 0.080 |
Why?
| | Clinical Competence | 1 | 2018 | 1247 | 0.070 |
Why?
| | Urine | 1 | 1989 | 64 | 0.070 |
Why?
| | Antigens, Protozoan | 1 | 1989 | 32 | 0.070 |
Why?
| | Sebaceous Gland Neoplasms | 1 | 1989 | 3 | 0.070 |
Why?
| | Eyelid Neoplasms | 1 | 1989 | 10 | 0.070 |
Why?
| | Odds Ratio | 4 | 2019 | 1083 | 0.070 |
Why?
| | Blood Chemical Analysis | 1 | 1989 | 109 | 0.070 |
Why?
| | Eye | 7 | 1988 | 112 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2024 | 2028 | 0.070 |
Why?
| | Postoperative Period | 2 | 2019 | 351 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 8 | 2019 | 849 | 0.070 |
Why?
| | Antibody Formation | 3 | 1985 | 288 | 0.060 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 1987 | 19 | 0.060 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4568 | 0.060 |
Why?
| | Dextrans | 1 | 1987 | 84 | 0.060 |
Why?
| | Autoantibodies | 6 | 1992 | 1509 | 0.060 |
Why?
| | Fanconi Syndrome | 1 | 1986 | 2 | 0.060 |
Why?
| | Escherichia coli | 1 | 1991 | 835 | 0.060 |
Why?
| | Prednisolone | 2 | 2020 | 67 | 0.060 |
Why?
| | Immunoenzyme Techniques | 8 | 1991 | 200 | 0.060 |
Why?
| | Lymphocyte Transfusion | 1 | 1986 | 20 | 0.060 |
Why?
| | Cell Movement | 2 | 1988 | 961 | 0.060 |
Why?
| | Interferometry | 1 | 1985 | 6 | 0.060 |
Why?
| | Lasers | 2 | 1985 | 127 | 0.060 |
Why?
| | Phenotype | 4 | 2022 | 3170 | 0.060 |
Why?
| | Lenses, Intraocular | 2 | 2021 | 49 | 0.060 |
Why?
| | Electroretinography | 1 | 2025 | 51 | 0.060 |
Why?
| | Panophthalmitis | 1 | 1985 | 2 | 0.060 |
Why?
| | Antibodies, Bispecific | 1 | 2026 | 68 | 0.050 |
Why?
| | Atrophy | 1 | 2025 | 199 | 0.050 |
Why?
| | Double-Blind Method | 4 | 2026 | 2064 | 0.050 |
Why?
| | Lubricant Eye Drops | 1 | 2024 | 9 | 0.050 |
Why?
| | Uveomeningoencephalitic Syndrome | 3 | 1990 | 7 | 0.050 |
Why?
| | Angiogenesis Inhibitors | 1 | 2026 | 239 | 0.050 |
Why?
| | Biopsy | 5 | 1993 | 1082 | 0.050 |
Why?
| | Protein S Deficiency | 1 | 2004 | 8 | 0.050 |
Why?
| | Choroiditis | 4 | 1991 | 6 | 0.050 |
Why?
| | Endemic Diseases | 1 | 2024 | 33 | 0.050 |
Why?
| | Myopia | 1 | 1984 | 59 | 0.050 |
Why?
| | Microscopy, Electron | 8 | 1988 | 414 | 0.050 |
Why?
| | Phagocyte Bactericidal Dysfunction | 1 | 1983 | 11 | 0.050 |
Why?
| | Tears | 4 | 1987 | 27 | 0.050 |
Why?
| | Retinal Artery | 2 | 1987 | 17 | 0.050 |
Why?
| | Ophthalmia, Sympathetic | 3 | 1990 | 3 | 0.050 |
Why?
| | Tretinoin | 1 | 1984 | 125 | 0.050 |
Why?
| | Viremia | 1 | 2024 | 160 | 0.050 |
Why?
| | Keratoplasty, Penetrating | 2 | 1994 | 9 | 0.050 |
Why?
| | Immunocompromised Host | 1 | 2024 | 202 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 207 | 0.050 |
Why?
| | Immunologic Memory | 1 | 1985 | 368 | 0.050 |
Why?
| | Transplant Recipients | 1 | 2024 | 182 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Immunohistochemistry | 6 | 1993 | 1723 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2020 | 3634 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2025 | 2967 | 0.040 |
Why?
| | Deltaretrovirus | 3 | 1986 | 12 | 0.040 |
Why?
| | Aneurysm | 1 | 1982 | 37 | 0.040 |
Why?
| | Cavernous Sinus | 1 | 1981 | 16 | 0.040 |
Why?
| | Adenocarcinoma | 1 | 1989 | 926 | 0.040 |
Why?
| | 2-Aminopurine | 1 | 2001 | 10 | 0.040 |
Why?
| | Herpes Zoster Ophthalmicus | 1 | 2001 | 6 | 0.040 |
Why?
| | Infusions, Intravenous | 2 | 2020 | 428 | 0.040 |
Why?
| | Arteriovenous Fistula | 1 | 1981 | 38 | 0.040 |
Why?
| | Pigment Epithelium of Eye | 4 | 1990 | 36 | 0.040 |
Why?
| | Transplantation Tolerance | 1 | 2021 | 39 | 0.040 |
Why?
| | Fibrinogen | 1 | 2022 | 180 | 0.040 |
Why?
| | Abatacept | 1 | 2021 | 56 | 0.040 |
Why?
| | Cyclopentolate | 1 | 2020 | 3 | 0.040 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 62 | 0.040 |
Why?
| | Microscopy, Acoustic | 1 | 2020 | 10 | 0.040 |
Why?
| | Gonioscopy | 1 | 2020 | 11 | 0.040 |
Why?
| | Administration, Ophthalmic | 1 | 2020 | 16 | 0.040 |
Why?
| | Mycobacterium tuberculosis | 1 | 2024 | 318 | 0.040 |
Why?
| | Muscarinic Antagonists | 1 | 2020 | 30 | 0.040 |
Why?
| | Amyloidosis | 1 | 2020 | 45 | 0.040 |
Why?
| | Carotid Arteries | 1 | 1981 | 208 | 0.040 |
Why?
| | Epithelium | 6 | 1991 | 311 | 0.040 |
Why?
| | Kidney | 3 | 1989 | 1496 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 99 | 0.040 |
Why?
| | Immunization, Passive | 3 | 1988 | 90 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2021 | 423 | 0.040 |
Why?
| | Sarcoma, Kaposi | 4 | 1999 | 83 | 0.040 |
Why?
| | Hypertension | 5 | 1991 | 1276 | 0.040 |
Why?
| | Drug Combinations | 1 | 2020 | 396 | 0.040 |
Why?
| | Cytosine | 1 | 1998 | 49 | 0.040 |
Why?
| | Trabecular Meshwork | 1 | 2019 | 74 | 0.040 |
Why?
| | Cornea | 4 | 1989 | 154 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2024 | 2123 | 0.030 |
Why?
| | Anticoagulants | 1 | 2004 | 748 | 0.030 |
Why?
| | Prolactin | 2 | 1988 | 87 | 0.030 |
Why?
| | CD4 Lymphocyte Count | 1 | 1998 | 280 | 0.030 |
Why?
| | Conjunctiva | 3 | 1989 | 52 | 0.030 |
Why?
| | Logistic Models | 2 | 2019 | 2139 | 0.030 |
Why?
| | Organophosphorus Compounds | 1 | 1998 | 84 | 0.030 |
Why?
| | Retinol-Binding Proteins | 2 | 1988 | 17 | 0.030 |
Why?
| | Fluorometholone | 1 | 2017 | 4 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2020 | 554 | 0.030 |
Why?
| | Hereditary Autoinflammatory Diseases | 1 | 2017 | 13 | 0.030 |
Why?
| | Drug Evaluation | 2 | 1988 | 79 | 0.030 |
Why?
| | Group Processes | 1 | 2017 | 63 | 0.030 |
Why?
| | North America | 1 | 2018 | 303 | 0.030 |
Why?
| | Chemotaxis, Leukocyte | 2 | 1987 | 114 | 0.030 |
Why?
| | Nod2 Signaling Adaptor Protein | 1 | 2017 | 34 | 0.030 |
Why?
| | Cattle | 5 | 1991 | 946 | 0.030 |
Why?
| | HLA-DR Antigens | 5 | 1991 | 220 | 0.030 |
Why?
| | Cytokines | 1 | 2025 | 2069 | 0.030 |
Why?
| | Administration, Oral | 3 | 1999 | 867 | 0.030 |
Why?
| | Interferon-gamma | 2 | 1991 | 784 | 0.030 |
Why?
| | Properdin | 1 | 1976 | 9 | 0.030 |
Why?
| | Observer Variation | 1 | 2017 | 357 | 0.030 |
Why?
| | Rats, Inbred Strains | 5 | 1987 | 321 | 0.030 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2016 | 24 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 789 | 0.030 |
Why?
| | Plasma Cells | 2 | 1987 | 80 | 0.030 |
Why?
| | Drug Resistance, Microbial | 1 | 1996 | 64 | 0.030 |
Why?
| | ROC Curve | 1 | 2018 | 618 | 0.030 |
Why?
| | Proteins | 2 | 2020 | 1023 | 0.030 |
Why?
| | Chronic Disease | 4 | 1990 | 1812 | 0.030 |
Why?
| | Magnesium | 2 | 1986 | 157 | 0.030 |
Why?
| | Syndrome | 2 | 1987 | 381 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1547 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 688 | 0.030 |
Why?
| | Blood Proteins | 2 | 1989 | 239 | 0.030 |
Why?
| | Glycoproteins | 1 | 1976 | 354 | 0.030 |
Why?
| | Conjunctival Neoplasms | 2 | 1984 | 7 | 0.030 |
Why?
| | Retinal Hemorrhage | 2 | 1986 | 21 | 0.030 |
Why?
| | Diagnosis, Differential | 2 | 1988 | 1512 | 0.030 |
Why?
| | HIV Infections | 1 | 2009 | 3195 | 0.030 |
Why?
| | Recurrence | 2 | 1988 | 1139 | 0.030 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2017 | 293 | 0.020 |
Why?
| | Proteomics | 1 | 2020 | 1188 | 0.020 |
Why?
| | Immunization | 2 | 1985 | 375 | 0.020 |
Why?
| | Granulomatous Disease, Chronic | 2 | 1983 | 49 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 4 | 1989 | 365 | 0.020 |
Why?
| | Antibodies, Antinuclear | 2 | 1992 | 62 | 0.020 |
Why?
| | Models, Biological | 2 | 2016 | 1764 | 0.020 |
Why?
| | Immunity, Cellular | 2 | 1985 | 274 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 7 | 1994 | 411 | 0.020 |
Why?
| | Dinoprostone | 2 | 1990 | 180 | 0.020 |
Why?
| | Cells, Cultured | 5 | 1991 | 4151 | 0.020 |
Why?
| | Eye Infections | 1 | 1992 | 3 | 0.020 |
Why?
| | Cell Line | 5 | 1991 | 2823 | 0.020 |
Why?
| | Models, Statistical | 1 | 2016 | 672 | 0.020 |
Why?
| | Kinetics | 2 | 1988 | 1568 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2021 | 1399 | 0.020 |
Why?
| | Epitopes | 3 | 1990 | 473 | 0.020 |
Why?
| | Propionibacterium acnes | 1 | 1991 | 10 | 0.020 |
Why?
| | Indomethacin | 2 | 1990 | 76 | 0.020 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 2 | 1989 | 104 | 0.020 |
Why?
| | Transforming Growth Factor beta | 2 | 1991 | 474 | 0.020 |
Why?
| | Sepsis | 2 | 1984 | 664 | 0.020 |
Why?
| | Biological Transport, Active | 1 | 1991 | 69 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2933 | 0.020 |
Why?
| | Immunoglobulin lambda-Chains | 1 | 1990 | 9 | 0.020 |
Why?
| | Dogs | 2 | 1990 | 478 | 0.020 |
Why?
| | B-Lymphocytes | 2 | 1987 | 872 | 0.020 |
Why?
| | Microcirculation | 1 | 1991 | 142 | 0.020 |
Why?
| | Random Allocation | 2 | 1988 | 365 | 0.020 |
Why?
| | Coronary Circulation | 1 | 1991 | 134 | 0.020 |
Why?
| | Cefazolin | 1 | 1990 | 22 | 0.020 |
Why?
| | Endothelium, Corneal | 1 | 1990 | 19 | 0.020 |
Why?
| | Recombinant Proteins | 2 | 1991 | 1368 | 0.020 |
Why?
| | Fluorescein | 1 | 1989 | 24 | 0.020 |
Why?
| | Protein Binding | 2 | 1989 | 2240 | 0.020 |
Why?
| | Kidney Function Tests | 2 | 1989 | 156 | 0.020 |
Why?
| | Flow Cytometry | 2 | 1992 | 1165 | 0.020 |
Why?
| | Osmolar Concentration | 1 | 1989 | 168 | 0.020 |
Why?
| | Retroviridae Proteins | 1 | 1989 | 10 | 0.020 |
Why?
| | Diagnostic Errors | 1 | 1990 | 178 | 0.020 |
Why?
| | Hemocyanins | 2 | 1988 | 61 | 0.020 |
Why?
| | Antimetabolites | 1 | 1989 | 21 | 0.020 |
Why?
| | Alkylating Agents | 1 | 1989 | 24 | 0.020 |
Why?
| | Heptanoates | 1 | 1988 | 2 | 0.020 |
Why?
| | Drug Eruptions | 1 | 1989 | 28 | 0.020 |
Why?
| | Interferon Type I | 1 | 1990 | 147 | 0.020 |
Why?
| | Suramin | 1 | 1988 | 8 | 0.020 |
Why?
| | HIV Envelope Protein gp120 | 1 | 1989 | 55 | 0.020 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1989 | 34 | 0.020 |
Why?
| | Candidiasis | 1 | 1989 | 64 | 0.020 |
Why?
| | Toxoplasmosis | 1 | 1989 | 43 | 0.020 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 1989 | 87 | 0.020 |
Why?
| | Lung Diseases | 2 | 1986 | 782 | 0.020 |
Why?
| | Mycobacterium Infections | 1 | 1989 | 55 | 0.020 |
Why?
| | Heptanoic Acids | 1 | 1988 | 67 | 0.020 |
Why?
| | Receptors, Virus | 1 | 1989 | 95 | 0.020 |
Why?
| | Placebos | 1 | 1988 | 193 | 0.020 |
Why?
| | Antigen-Antibody Complex | 2 | 1985 | 69 | 0.020 |
Why?
| | Corneal Injuries | 1 | 1989 | 42 | 0.020 |
Why?
| | HIV Seropositivity | 1 | 1989 | 119 | 0.020 |
Why?
| | Injections | 1 | 1989 | 199 | 0.020 |
Why?
| | Lens, Crystalline | 1 | 1990 | 136 | 0.020 |
Why?
| | Dexamethasone | 2 | 1987 | 365 | 0.020 |
Why?
| | Central Nervous System Diseases | 1 | 1989 | 74 | 0.020 |
Why?
| | Sugar Alcohol Dehydrogenases | 1 | 1987 | 2 | 0.020 |
Why?
| | Imidazolidines | 1 | 1987 | 10 | 0.020 |
Why?
| | Colchicine | 1 | 1987 | 21 | 0.020 |
Why?
| | Elapid Venoms | 1 | 1987 | 13 | 0.020 |
Why?
| | Blood-Retinal Barrier | 1 | 1987 | 13 | 0.020 |
Why?
| | Receptors, Interleukin-2 | 1 | 1987 | 64 | 0.020 |
Why?
| | Aldehyde Reductase | 1 | 1987 | 31 | 0.020 |
Why?
| | Specific Gravity | 1 | 1987 | 13 | 0.020 |
Why?
| | Antigens, Differentiation | 1 | 1987 | 76 | 0.020 |
Why?
| | Galactosemias | 1 | 1987 | 16 | 0.020 |
Why?
| | Community Health Services | 1 | 2009 | 231 | 0.020 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 1987 | 6 | 0.020 |
Why?
| | Herpesviridae Infections | 1 | 1989 | 148 | 0.020 |
Why?
| | Prednisone | 2 | 1986 | 226 | 0.020 |
Why?
| | Pituitary-Adrenal System | 1 | 1989 | 164 | 0.020 |
Why?
| | Down-Regulation | 1 | 1990 | 618 | 0.020 |
Why?
| | Drug Interactions | 1 | 1989 | 405 | 0.020 |
Why?
| | Onchocerciasis | 1 | 1987 | 8 | 0.020 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 1989 | 199 | 0.020 |
Why?
| | Organ Specificity | 1 | 1987 | 309 | 0.020 |
Why?
| | Molecular Weight | 1 | 1987 | 312 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 1990 | 574 | 0.020 |
Why?
| | Sclera | 1 | 1987 | 36 | 0.020 |
Why?
| | Heart Rate | 1 | 1991 | 856 | 0.020 |
Why?
| | Macaca mulatta | 1 | 1987 | 186 | 0.020 |
Why?
| | Dihydroergotoxine | 1 | 1986 | 1 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 1990 | 858 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 1987 | 209 | 0.020 |
Why?
| | Indium | 1 | 1986 | 8 | 0.020 |
Why?
| | Imidazoles | 1 | 1987 | 247 | 0.010 |
Why?
| | Muramidase | 1 | 1986 | 67 | 0.010 |
Why?
| | Peritoneal Cavity | 1 | 1986 | 30 | 0.010 |
Why?
| | Radioisotopes | 1 | 1986 | 37 | 0.010 |
Why?
| | Wound Healing | 1 | 1989 | 355 | 0.010 |
Why?
| | Serum Albumin | 1 | 1986 | 147 | 0.010 |
Why?
| | Mutation | 1 | 2017 | 4090 | 0.010 |
Why?
| | Osteoporosis | 1 | 1989 | 239 | 0.010 |
Why?
| | Reference Values | 4 | 1989 | 798 | 0.010 |
Why?
| | Peptide Fragments | 1 | 1990 | 696 | 0.010 |
Why?
| | Immune Tolerance | 1 | 1988 | 385 | 0.010 |
Why?
| | Rabbits | 1 | 1986 | 653 | 0.010 |
Why?
| | Vascular Diseases | 1 | 1988 | 252 | 0.010 |
Why?
| | Connective Tissue | 1 | 1985 | 38 | 0.010 |
Why?
| | Pigmentation Disorders | 1 | 1985 | 8 | 0.010 |
Why?
| | Tetanus Toxoid | 1 | 1985 | 34 | 0.010 |
Why?
| | Acute Disease | 2 | 1987 | 1036 | 0.010 |
Why?
| | Prognosis | 2 | 1985 | 4329 | 0.010 |
Why?
| | Retinitis Pigmentosa | 1 | 1984 | 20 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1985 | 335 | 0.010 |
Why?
| | Salmonella typhimurium | 1 | 1986 | 188 | 0.010 |
Why?
| | Lymphadenitis | 1 | 1984 | 6 | 0.010 |
Why?
| | Potassium | 1 | 1985 | 152 | 0.010 |
Why?
| | Blood Sedimentation | 1 | 1984 | 37 | 0.010 |
Why?
| | Antibodies | 1 | 1987 | 397 | 0.010 |
Why?
| | Kidney Glomerulus | 1 | 1985 | 125 | 0.010 |
Why?
| | Fibrosis | 1 | 1987 | 561 | 0.010 |
Why?
| | Kidney Tubules, Proximal | 1 | 1985 | 129 | 0.010 |
Why?
| | Chlorides | 1 | 1985 | 138 | 0.010 |
Why?
| | Isotretinoin | 1 | 1984 | 26 | 0.010 |
Why?
| | Acne Vulgaris | 1 | 1984 | 25 | 0.010 |
Why?
| | Complement C3 | 1 | 1985 | 187 | 0.010 |
Why?
| | Uveal Diseases | 1 | 1983 | 6 | 0.010 |
Why?
| | Optic Neuritis | 1 | 1984 | 44 | 0.010 |
Why?
| | Peptides | 1 | 1990 | 998 | 0.010 |
Why?
| | Carbon Dioxide | 1 | 1985 | 227 | 0.010 |
Why?
| | Oculomotor Muscles | 1 | 1984 | 86 | 0.010 |
Why?
| | Chediak-Higashi Syndrome | 1 | 1983 | 7 | 0.010 |
Why?
| | Uric Acid | 1 | 1984 | 167 | 0.010 |
Why?
| | Rats, Inbred BN | 2 | 1994 | 56 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2009 | 868 | 0.010 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 1984 | 138 | 0.010 |
Why?
| | Anemia | 1 | 1984 | 191 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1986 | 1270 | 0.010 |
Why?
| | Kidney Failure, Chronic | 1 | 1989 | 599 | 0.010 |
Why?
| | Liver Diseases | 1 | 1986 | 305 | 0.010 |
Why?
| | Fluorometry | 1 | 1981 | 19 | 0.010 |
Why?
| | Immunochemistry | 3 | 1986 | 12 | 0.010 |
Why?
| | Melanosis | 1 | 1981 | 16 | 0.010 |
Why?
| | Computers | 1 | 1981 | 66 | 0.010 |
Why?
| | Histocytochemistry | 3 | 1986 | 78 | 0.010 |
Why?
| | Liver | 1 | 1990 | 1899 | 0.010 |
Why?
| | Eyelid Diseases | 1 | 1981 | 26 | 0.010 |
Why?
| | Edema | 1 | 1982 | 125 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 1985 | 892 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2001 | 330 | 0.010 |
Why?
| | Calcium | 1 | 1986 | 1191 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 1994 | 177 | 0.010 |
Why?
| | HLA-DQ Antigens | 2 | 1991 | 174 | 0.010 |
Why?
| | Protease Inhibitors | 1 | 1999 | 102 | 0.010 |
Why?
| | Arthus Reaction | 2 | 1987 | 2 | 0.010 |
Why?
| | Permeability | 2 | 1987 | 169 | 0.010 |
Why?
| | Sucrose | 2 | 1987 | 114 | 0.010 |
Why?
| | Photoreceptor Cells | 2 | 1987 | 18 | 0.010 |
Why?
| | Survival Analysis | 1 | 1999 | 1378 | 0.010 |
Why?
| | Immunologic Techniques | 2 | 1986 | 38 | 0.010 |
Why?
| | Macrophages | 2 | 1994 | 1507 | 0.010 |
Why?
| | Transplantation, Isogeneic | 1 | 1994 | 17 | 0.010 |
Why?
| | Blotting, Southern | 1 | 1994 | 85 | 0.010 |
Why?
| | DNA, Protozoan | 1 | 1994 | 32 | 0.010 |
Why?
| | Tissue Donors | 2 | 1989 | 420 | 0.010 |
Why?
| | Shock, Septic | 1 | 1976 | 227 | 0.010 |
Why?
| | Eye Enucleation | 1 | 1993 | 15 | 0.010 |
Why?
| | Didanosine | 1 | 1993 | 13 | 0.010 |
Why?
| | Viral Proteins | 2 | 1985 | 350 | 0.010 |
Why?
| | Zidovudine | 1 | 1993 | 77 | 0.010 |
Why?
| | Drug Tolerance | 1 | 1993 | 99 | 0.010 |
Why?
| | Mice | 2 | 1986 | 18355 | 0.010 |
Why?
| | Neutrophils | 2 | 1987 | 1125 | 0.010 |
Why?
| | Cell Cycle | 1 | 1994 | 598 | 0.010 |
Why?
| | HLA-DP Antigens | 1 | 1991 | 32 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 1991 | 272 | 0.010 |
Why?
| | Thromboxane A2 | 1 | 1990 | 9 | 0.000 |
Why?
| | Leukotriene B4 | 1 | 1990 | 36 | 0.000 |
Why?
| | Histocompatibility Testing | 1 | 1990 | 123 | 0.000 |
Why?
| | Antigen-Presenting Cells | 1 | 1990 | 159 | 0.000 |
Why?
| | Biological Assay | 1 | 1991 | 132 | 0.000 |
Why?
| | Radioimmunoassay | 1 | 1990 | 165 | 0.000 |
Why?
| | Aspartate Aminotransferases | 1 | 1990 | 85 | 0.000 |
Why?
| | Immunophenotyping | 1 | 1991 | 322 | 0.000 |
Why?
| | Alanine Transaminase | 1 | 1990 | 151 | 0.000 |
Why?
| | Alkaline Phosphatase | 1 | 1990 | 144 | 0.000 |
Why?
| | T-Lymphocyte Subsets | 1 | 1992 | 420 | 0.000 |
Why?
| | Epoprostenol | 1 | 1990 | 132 | 0.000 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 1992 | 238 | 0.000 |
Why?
| | Immunoglobulins | 1 | 1990 | 163 | 0.000 |
Why?
| | Coroners and Medical Examiners | 1 | 1989 | 8 | 0.000 |
Why?
| | Virus Cultivation | 1 | 1989 | 31 | 0.000 |
Why?
| | Adrenal Cortex | 1 | 1988 | 33 | 0.000 |
Why?
| | Methods | 1 | 1988 | 68 | 0.000 |
Why?
| | Chemical Fractionation | 1 | 1988 | 29 | 0.000 |
Why?
| | Arterioles | 1 | 1988 | 52 | 0.000 |
Why?
| | Metaraminol | 1 | 1987 | 1 | 0.000 |
Why?
| | Survival Rate | 1 | 1993 | 2094 | 0.000 |
Why?
| | Rats, Inbred SHR | 1 | 1987 | 36 | 0.000 |
Why?
| | Rats, Inbred WKY | 1 | 1987 | 35 | 0.000 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 1988 | 122 | 0.000 |
Why?
| | Peroxidases | 1 | 1987 | 28 | 0.000 |
Why?
| | Mannitol | 1 | 1987 | 40 | 0.000 |
Why?
| | Adrenal Gland Neoplasms | 1 | 1988 | 98 | 0.000 |
Why?
| | Cell Membrane Permeability | 1 | 1987 | 88 | 0.000 |
Why?
| | Edetic Acid | 1 | 1987 | 47 | 0.000 |
Why?
| | Leukocyte Count | 1 | 1988 | 318 | 0.000 |
Why?
| | HIV Antigens | 1 | 1987 | 17 | 0.000 |
Why?
| | AIDS-Related Complex | 1 | 1986 | 4 | 0.000 |
Why?
| | Propionibacterium | 1 | 1986 | 3 | 0.000 |
Why?
| | Serum Albumin, Bovine | 1 | 1987 | 62 | 0.000 |
Why?
| | Mitosis | 1 | 1988 | 193 | 0.000 |
Why?
| | Carcinoma | 1 | 1988 | 227 | 0.000 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1986 | 39 | 0.000 |
Why?
| | Argon | 1 | 1986 | 21 | 0.000 |
Why?
| | Cell Division | 1 | 1988 | 757 | 0.000 |
Why?
| | Interleukin-1 | 1 | 1990 | 961 | 0.000 |
Why?
| | Blood-Brain Barrier | 1 | 1987 | 160 | 0.000 |
Why?
| | Homosexuality | 1 | 1986 | 17 | 0.000 |
Why?
| | Agranulocytosis | 1 | 1986 | 30 | 0.000 |
Why?
| | Antigens, Viral | 1 | 1987 | 182 | 0.000 |
Why?
| | Amino Acid Sequence | 1 | 1990 | 2131 | 0.000 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1985 | 35 | 0.000 |
Why?
| | Hydrogen Peroxide | 1 | 1987 | 335 | 0.000 |
Why?
| | Light | 1 | 1988 | 403 | 0.000 |
Why?
| | Regional Blood Flow | 1 | 1987 | 514 | 0.000 |
Why?
| | Molecular Sequence Data | 1 | 1990 | 2883 | 0.000 |
Why?
| | Drug Synergism | 1 | 1986 | 354 | 0.000 |
Why?
| | Indians, North American | 1 | 1990 | 598 | 0.000 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1986 | 196 | 0.000 |
Why?
| | Autoantigens | 1 | 1988 | 427 | 0.000 |
Why?
| | DNA | 1 | 1992 | 1437 | 0.000 |
Why?
| | HLA-B27 Antigen | 1 | 1985 | 16 | 0.000 |
Why?
| | Anterior Eye Segment | 1 | 1985 | 10 | 0.000 |
Why?
| | Hyperemia | 1 | 1985 | 49 | 0.000 |
Why?
| | Tissue and Organ Procurement | 1 | 1989 | 343 | 0.000 |
Why?
| | Biomarkers, Tumor | 1 | 1992 | 1329 | 0.000 |
Why?
| | Lymphokines | 1 | 1984 | 128 | 0.000 |
Why?
| | Structure-Activity Relationship | 1 | 1986 | 563 | 0.000 |
Why?
| | Gram-Negative Bacteria | 1 | 1985 | 80 | 0.000 |
Why?
| | Epithelial Cells | 1 | 1991 | 1134 | 0.000 |
Why?
| | Pilot Projects | 1 | 1990 | 1897 | 0.000 |
Why?
| | Ischemia | 1 | 1987 | 422 | 0.000 |
Why?
| | Monocytes | 1 | 1987 | 539 | 0.000 |
Why?
| | Brain Neoplasms | 1 | 1993 | 1331 | 0.000 |
Why?
| | Hodgkin Disease | 1 | 1986 | 172 | 0.000 |
Why?
| | Lymphatic Diseases | 1 | 1983 | 21 | 0.000 |
Why?
| | alpha 1-Antitrypsin | 1 | 1985 | 104 | 0.000 |
Why?
| | Cryptococcosis | 1 | 1984 | 31 | 0.000 |
Why?
| | Clone Cells | 1 | 1984 | 263 | 0.000 |
Why?
| | Prevalence | 1 | 1990 | 2874 | 0.000 |
Why?
| | Colitis | 1 | 1986 | 281 | 0.000 |
Why?
| | Pain | 1 | 1988 | 791 | 0.000 |
Why?
| | Meningitis | 1 | 1984 | 80 | 0.000 |
Why?
| | Antibodies, Viral | 1 | 1986 | 674 | 0.000 |
Why?
| | Microscopy, Fluorescence | 1 | 1984 | 408 | 0.000 |
Why?
| | Vasodilation | 1 | 1985 | 521 | 0.000 |
Why?
| | Kidney Transplantation | 1 | 1988 | 712 | 0.000 |
Why?
| | Mice, Inbred BALB C | 1 | 1984 | 1261 | 0.000 |
Why?
| | Endothelium, Vascular | 1 | 1988 | 956 | 0.000 |
Why?
| | Biomechanical Phenomena | 1 | 1985 | 860 | 0.000 |
Why?
| | Clinical Trials as Topic | 1 | 1986 | 1062 | 0.000 |
Why?
| | Blood Pressure | 1 | 1987 | 1782 | 0.000 |
Why?
| | Pneumonia, Viral | 1 | 1986 | 391 | 0.000 |
Why?
| | Killer Cells, Natural | 1 | 1983 | 481 | 0.000 |
Why?
| | Sexual Behavior | 1 | 1984 | 495 | 0.000 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 1984 | 339 | 0.000 |
Why?
| | Lung | 1 | 1985 | 4116 | 0.000 |
Why?
|
|
Palestine's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|